WX-293
WX-293 is a highly selective urokinase-type plasminogen activator (uPA) inhibitor with a Ki value of 2.4 μM. WX-293 abolishes hypoxia-induced keratinocyte migration and in vitro wound closure. WX-293 can be used in research on hypoxia-mediated skin wounds and solid malignant tumors.
For research use only. We do not sell to patients.
- CAS No.: 282718-42-7
- Formula: C19H27N5O
- Molecular Weight:341.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
WX-293 (0.1-0.2 μM; 16 h) inhibits hypoxia-induced in vitro wound healing of PAM 212 mouse keratinocytes in a concentration-dependent manner[1].
WX-293 potently and selectively inhibits purified human urokinase-type plasminogen activator (uPA) with a Ki value of 2.4 µM, and its mechanism of action involves targeting the S1′ pocket of uPA via a non-traditional binding mode[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PAM 212 murine keratinocytes
-
Concentration:0.1 μM, 0.2 μM
-
Incubation Time:16 h
-
Result:Inhibited hypoxia-enhanced wound closure by 70% (0.1 μM).
Inhibited uPA activity by 55.3% (0.1 μM).
Completely abolished hypoxia-enhanced wound closure (0.2 μM).
Inhibited uPA activity by 74.0% (0.2 μM).
Exhibited no effect on wound closure in normoxic cultures at either concentration.
Chemical Information
-
CAS No. 282718-42-7
-
Molecular Weight 341.45
-
Formula C19H27N5O
-
SMILES
O=C(NC12CC3CC(C2)CC(C1)C3)NCC4=CC=C(NC(N)=N)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Daniel RJ, et al. Increased migration of murine keratinocytes under hypoxia is mediated by induction of urokinase plasminogen activator. J Invest Dermatol. 2002;119(6):1304-1309. [Content Brief]
[2]. Muehlenweg B, et al. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin Biol Ther. 2001;1(4):683-691. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
WX-293 Related Classifications
HY-182450 Related Classifications
Powered by Bioz